| Jessie Upson, RN | |
|
1037 S Craftsbury Rd, Craftsbury, VT 05826-8008 | |
| (802) 424-7809 | |
| Not Available |
| Full Name | Jessie Upson |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse |
| Location | 1037 S Craftsbury Rd, Craftsbury, Vermont |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497529846 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 026.0097298 (Vermont) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jessie Upson, RN 1154 W Hill Rd, Hardwick, VT 05843-6501 Ph: (802) 424-7809 | Jessie Upson, RN 1037 S Craftsbury Rd, Craftsbury, VT 05826-8008 Ph: (802) 424-7809 |
News Archive
Providence Holy Cross Medical Center has embarked on a technology upgrade, funded by a $500,000 grant from Verizon, that will improve the hospital's efficiency, increase accuracy of patient records, and initiate health care outreach for uninsured Californians.
On Tuesday, Ambassador Johnnie Carson, assistant secretary for African Affairs; Reuben Brigety, principal deputy assistant secretary in the Bureau of Population, Refugees, and Migration; Ambassador Donald Steinberg, USAID deputy administrator; and USAID Assistant Administrator Nancy Lindborg held a special press briefing to discuss the humanitarian crisis in the Horn of Africa, according to this post on the State Department's "DipNote" blog.
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas.
Polyarticular Juvenile Idiopathic Arthritis (PJIA) is a type of Juvenile Idiopathic Arthritis (JIA), a group of Rheumatoid Arthritis (RA) diseases that manifests in multiple ways in children.
BiondVax Pharmaceuticals Ltd., an Israeli biopharmaceutical company at the forefront of global efforts towards the development of a Universal Influenza Vaccine, today announced that it has begun to immunize subjects in a Phase IIa clinical trial of the Multimeric-001 Universal Flu Vaccine candidate. The study will evaluate the safety and immunogenicity of the Multimeric-001 vaccine.
› Verified 5 days ago